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Human SARS-CoV-2 infection is characterized by a high mortality rate due to some patients developing a large innate immune
response associated with a cytokine storm and acute respiratory distress syndrome (ARDS). This is characterized at the
molecular level by decreased energy metabolism, altered redox state, oxidative damage, and cell death. Therapies that increase
levels of (R)-beta-hydroxybutyrate (R-BHB), such as the ketogenic diet or consuming exogenous ketones, should restore altered
energy metabolism and redox state. R-BHB activates anti-inﬂammatory GPR109A signaling and inhibits the NLRP3
inﬂammasome and histone deacetylases, while a ketogenic diet has been shown to protect mice from inﬂuenza virus infection
through a protective γδ T cell response and by increasing electron transport chain gene expression to restore energy
metabolism. During a virus-induced cytokine storm, metabolic ﬂexibility is compromised due to increased levels of reactive
oxygen species (ROS) and reactive nitrogen species (RNS) that damage, downregulate, or inactivate many enzymes of central
metabolism including the pyruvate dehydrogenase complex (PDC). This leads to an energy and redox crisis that decreases B
and T cell proliferation and results in increased cytokine production and cell death. It is hypothesized that a moderately high-fat
diet together with exogenous ketone supplementation at the ﬁrst signs of respiratory distress will increase mitochondrial
metabolism by bypassing the block at PDC. R-BHB-mediated restoration of nucleotide coenzyme ratios and redox state should
decrease ROS and RNS to blunt the innate immune response and the associated cytokine storm, allowing the proliferation of
cells responsible for adaptive immunity. Limitations of the proposed therapy include the following: it is unknown if human
immune and lung cell functions are enhanced by ketosis, the risk of ketoacidosis must be assessed prior to initiating treatment,
and permissive dietary fat and carbohydrate levels for exogenous ketones to boost immune function are not yet established. The
third limitation could be addressed by studies with inﬂuenza-infected mice. A clinical study is warranted where COVID-19
patients consume a permissive diet combined with ketone ester to raise blood ketone levels to 1 to 2 mM with measured
outcomes of symptom severity, length of infection, and case fatality rate.

1. Introduction
There are tremendous demands on governments and the private sector to solve the COVID-19 crisis with an eﬀective and
timely vaccine or therapy. As time passes, the demand for

information grows pertaining to how healthy lifestyle and
nutrition may play a role in protection against the detrimental outcomes of the SARS-CoV-2 virus. In this review, the
intricate and detailed interplay among nutrition, metabolism,
and the tightly controlled immune system is highlighted. The
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data suggest that exogenous ketones can increase cell eﬃciency and metabolic ﬂexibility to provide signiﬁcant
immune modulation. However, challenges remain in identifying the exact dietary macronutrient combinations that will
best inﬂuence the immune system. It is important for
researchers and clinicians to consider metabolic strategies
when attempting to identify novel preventative measures
for viral infection, as these therapies can support the patient’s
immune system while showing minimal toxicities. The
mechanisms through which exogenous ketones improve
energy and redox metabolism and blunt inﬂammation likely
apply not only to COVID-19 but to any viral or bacterial
infection where excessive cytokine production can lead to
multiple organ failure and mortality. There are many types
of metabolic therapies. However, therapies that increase RBHB levels, including the consumption of a ketogenic diet
or diﬀerent forms of exogenous ketones, will be the focus of
this review. Others have also suggested that increasing systemic ketone levels may aid host defenses against respiratory
viral infection, in part, by decreasing inﬂammation [1, 2],
including a recent comprehensive review [3], while a clinical
trial of the eﬀects of a ketogenic diet on intubated SARSCoV-2 patients has recently been registered (NCT04358835).
1.1. SARS-CoV-2 Infects Type II Alveolar Epithelial Cells and
Induces the Innate and Acquired Immune Responses. SARSCoV-2 infects many cell types including type II alveolar epithelial cells (AEC II) in the lungs [4], where this leads to
respiratory infection. AEC II either divide to maintain their
levels or diﬀerentiate into AEC type I, which provide the surface area for the vast majority of gas exchange in the lungs
[5]. Other important functions of AEC II include the secretion of surfactants, superoxide dismutase 3 (SOD3) [6], and
type I (α/β) and type III (λ) interferons [7] to protect airway
function. Due to these functions, AEC II have high energy
requirements and rely heavily on fatty acid oxidation for
energy production [8]. The partial loss of these functions
during infection facilitates viral spread and disrupts the
immune response and tissue repair. Nearly all nucleated cells,
including AEC II, can recognize the presence of viruses and
initiate an innate immune response to recruit phagocytic
cells to the infection. RNA viruses such as SARS-CoV-2 are
primarily recognized by cytosolic retinoic acid-inducible
gene I-like receptors (RLRs), RIG-1, and melanoma
diﬀerentiation-associated gene 5 (MDA5). The endosomal
toll-like receptors (TLRs), TLR7/8 and TLR3, also play a role
[9]. Excessive signaling through these endosomal TLRs can
cause inﬂammatory pathology [10]. In a cytokine storm,
the number of phagocytic cells, including macrophages and
neutrophils, increases along with the levels of proinﬂammatory cytokines, while the numbers of B and T lymphocytes,
mediators of the adaptive immune response, decline [11].
This results in a failure to clear the virus and facilitates a runaway positive feedback loop that increases the numbers of
cytokine-secreting innate immune cells. This cytokine storm
is emerging as a major contributor to acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and
patient death in COVID-19 [12, 13]. Figure 1 summarizes
the molecular pathologies that occur during SARS-CoV-2
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infection that lead to a cytokine storm and ARDS, while
Figure 2 summarizes how metabolic therapy with ketone
ester and a moderately high-fat diet may intervene in the disease process to protect against pathology.
1.2. Metabolic Therapy. Central metabolism is controlled by
four major nucleotide coenzyme couples: ADP/ATP,
NAD+/NADH, NADP+/NADPH, and acetyl-CoA/CoA
[14]. The prominent role these couples play in central metabolism is highlighted in Figure 3. Metabolic therapy aimed at
restoring these ratios is often used as an adjunct to more targeted therapies [15]. The ketogenic diet as a treatment for
childhood epilepsy has drawn focus to (R)-beta-hydroxybutyrate (R-BHB) as a metabolic therapy. Recently, exogenous
ketones, which are various formulations of BHB, acetoacetate, or their precursors, have made it possible to raise blood
R-BHB levels and alter the ratios of the controlling coenzyme
couples without implementing a ketogenic diet [16]. (R)-3Hydroxybutyl (R)-3-hydroxybutyrate, a type of ketone ester,
is one of the several forms of exogenous ketones that increase
systemic R-BHB levels. R-BHB-derived metabolites restore
ﬂux through the citric acid (Krebs) cycle and oxidative phosphorylation when viral-induced changes in enzyme activity
prevent glucose [17] or fatty acids [18, 19] from fueling these
pathways. Increasing R-BHB levels has been shown to normalize ADP/ATP, NAD+/NADH, NADP+/NADPH, and
acetyl-CoA/CoA ratios in diseased tissue [16]. R-BHB has
multiple anti-inﬂammatory signaling roles and functions as
an epigenetic modiﬁer to stimulate a program of gene expression that alters metabolism to restore cellular redox function.
The focus of metabolic therapy is on the restoration of the
coenzyme ratios that largely control metabolic ﬂux through
central metabolic pathways.
1.2.1. Ketone Ester Consumption Blunts Decreased Immune
Function in Humans. In a study of blood cytokine levels in
well-trained cyclists who compete in multiday races, the
levels of TNF-α, IL-6, IL-2, and IFN-γ were raised following
intense exercise, indicating increased inﬂammation, whereas
the level of IL-1β was unchanged [21]. On the last day of an
eighteen-day trial, cyclists given daily ketone ester (R)-3hydroxybutyl (R)-3-hydroxybutyrate showed a 15% higher
mean power output and 25% increase in the CD4+/CD8+
(T helper cells/cytotoxic T cells) ratio than controls [22].
An increased CD4+/CD8+ ratio is associated with increased
immune function [23], and this ratio declines with aging as
immune system function declines [24].
1.2.2. Ketone Ester Treatment Blunts the Cytokine Storm
Induced by Ionizing Radiation in Model Systems. The same
ketone ester used in the cycling studies has also been used
in radiation mitigation studies. Cytokines are central to the
pathophysiology of COVID-19; while some are beneﬁcial,
others are detrimental (IL-1β, IL-6, and TNF-α), at least in
the context of the cytokine storm [25–28]. Exposure to acute
doses of radiation results in tissue damage and an activation
of cytokine cascades [26]. Several pharmaceutical approaches
are being studied to prevent or decrease radiation-induced
tissue damage and the cascade of harmful cytokines [29].
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Figure 1: Mechanisms that lead to acute respiratory distress syndrome (ARDS) and mortality following SARS-CoV-2 infection are shown. The
cells of the innate immune response secrete increasing amounts of cytokines. The cells that normally protect against a cytokine storm lose this
ability leading to a runaway positive feedback loop of cytokine production. Abbreviations: 11β-HSD1 and 11β-HSD2: 11β-hydroxysteroid
dehydrogenase types 1 and 2; ACE2: angiotensin-converting enzyme 2; AEC I and AEC II: alveolar epithelial cell types I and II; DCs:
dendritic cells; FOXO1: forkhead box O1 transcription factor; FOXO3: forkhead box O3 transcription factor; HIF-1α: hypoxia-inducible
factor 1 alpha; IFN: interferon; IL-6: interleukin-6; IRF3: IFN-regulatory factor 3; NAD(H): nicotinamide adenine dinucleotide; NADP(H):
nicotinamide adenine dinucleotide phosphate; ONOO-: peroxynitrite; PGC1-α: PPARG coactivator 1-alpha; PDK1 and PDK4: pyruvate
dehydrogenase kinases 1 and 4; RLR: retinoic acid-inducible gene I-like receptors; RNS: reactive nitrogen species; ROS: reactive oxygen
species; SOD: superoxide dismutase; TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor-alpha.

There is interest in using this radiation countermeasure strategy as a model for a viral-induced cytokine storm. IR has
been shown to increase the expression of the following cytokines and growth factors including IL-4, IL-5, IL-10 [30],
TGF-β, IL-12, IL-18 [31], type I interferons, IL-1α, IL-1β,

IL-6, GM-CSF, and TNF-α [32, 33]. Maximal cytokine production occurs between 4 and 24 hours following exposure
to short-term radiation [34, 35]. The balance of proinﬂammatory and anti-inﬂammatory cytokines synthesized is critical in the determination of outcomes [36] with several factors
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Figure 2: Proposed mechanisms and time course of SARS-CoV-2 infection when using a ketone-based metabolic therapy. Abbreviations:
HBP: hexosamine biosynthesis pathway.

altering the proﬁles of the cytokines produced including the
speciﬁc animal species and tissue studied, the magnitude of
the radiation received, and whether whole animals, portions
of animals, or only cells were exposed [30–33]. Chronic
exposure to very low-dose nonacute radiation can induce
hormesis and alter the levels of several cytokines to improve
tissue responses [30, 35]. Further studies would be needed to
determine the mechanism of these acute versus subacute
radiation cytokine responses. Human polymorphisms in
cytokine genes have been shown to be responsible for the differences in the extent of pathology that occurs following radiation damage [31]. Limited IR studies with acute radiation
have demonstrated that ketone ester was able to decrease
chromosomal damage in mice and increase survival in cells
[37]. Ongoing studies are directly measuring the eﬀects of
ketone ester on animal survival following radiation and the
eﬀects on the radiation-induced cytokine storm. There are

several other therapies being tested against a radiationinduced cytokine storm that could be considered for the
treatment of COVID-19 as well [38].
1.3. Cytokines and Cytokine Receptors Are Also Promising
Targets to Treat a Cytokine Storm. Several planned or
recently initiated studies are targeting cytokines or their
receptors in an attempt to blunt the cytokine storm of
COVID-19. For example, the IL-6 receptor monoclonal antibody (mAb) antagonist tocilizumab has been identiﬁed as a
strong candidate for treatment [39]. Other potential treatments to limit cytokine signaling include sarilumab (IL-6R
mAb antagonist), anakinra (IL-1R recombinant protein
antagonist) [40], and emapalumab (IFN-γ mAb). Some cytokines, such as type I interferons, may be beneﬁcial to reduce
the cytokine storm. SARS-CoV-2 was shown to be quite susceptible to treatment with type I interferons in vitro [41]. IL-
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Figure 3: The major pathways of central metabolism and reactions that alter the ratios of coenzyme couples are shown. The mitochondrial
matrix and the cytoplasm have independent coenzyme couple ratios. ATP synthesized in the mitochondrial matrix is exported to the
cytoplasm in exchange for ADP by the adenine nucleotide translocase present in the inner mitochondrial membrane. Acetyl-CoA
synthesized in the mitochondrial matrix must also be exported to the cytoplasm to provide two carbon units for fatty acid synthesis and
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glycolysis leading to reduced cellular lactate export. Abbreviations: Glut1 and Glut3: glucose transporters 1 and 3; MCT: monocarboxylate
transporter; NNT: nicotinamide nucleotide transhydrogenase; PDC: pyruvate dehydrogenase complex.

6
7, which protects lymphocyte function, has been proposed as
a therapy to treat lymphopenia that contributes to the cytokine storm [42]. Therefore, clinical studies to determine the
eﬀects of metabolic therapy with exogenous ketones in combination with one of these more targeted therapies should be
considered for patients with severe SARS-CoV-2 infection.

2. R-BHB Decreases ROS/RNS Levels as a
Mechanism to Blunt the Cytokine Storm
2.1. Increased ROS Levels Stimulate Inﬂammasome Activity
and Cytokine Production. Reactive oxygen species (ROS)
and reactive nitrogen species (RNS) levels increase in the
lungs by at least two diﬀerent mechanisms during the viralinduced cytokine storm. First, viral RNA binding to TLRs
leads to decreased expression of mitochondrial electron
transport chain (ETC) genes, which increases mitochondrial
superoxide production [43–45]. Second, phagocytic cells are
recruited to the lungs and, together with resident lung phagocytes, are activated through TLR7 and RIG-1 to increase
NADPH oxidase 2 (NOX2) activity [46, 47], increasing the
production of both intracellular and extracellular ROS and
RNS to kill pathogens. However, host cells can be damaged
as a byproduct of this response, especially in a cytokine
storm. A review on the redox biology of respiratory viral
infections has recently been published [48]. The increased
ROS production from virus-induced TLR signaling [47],
RIG-1 signaling [46], and altered mitochondrial function
[49] leads to the activation of several transcriptional regulators such as NF-κB, IFN-regulatory factor 3 (IRF3), and
STAT1 to increase the production of cytokines, including
TNF-α, IL-6, and IL-8, from AEC and macrophages [50].
The enhanced NF-κB activity also leads to the activation of
the NLRP3 inﬂammasome that increases IL-1β and IL-18
production [51]. The transcription of NF-κB is a necessary
step in the two-stage model of NLRP3 activation [52].
2.2. Secreted SOD3 and Catalase and Exogenous ROS
Scavengers Protect against Extracellular ROS and Cytokine
Storm. In the lungs, catalase and extracellular superoxide dismutase 3 (SOD3) [6] are synthesized at high levels by AEC II
[53, 54]. In addition to its normal peroxisomal localization,
catalase is secreted to the extracellular space by alveolar macrophages [55, 56] through a mechanism that is distinct from
the classical secretory pathway [56, 57]. Older COVID-19
patients, who have a higher risk of mortality from the disease
[58], were shown to express much less SOD3 from their AEC
II than younger patients [59], suggesting an important role of
SOD3 in protecting against the cytokine storm. These antioxidant enzymes reduce the concentration of toxic superoxide
and hydrogen peroxide in extracellular ﬂuids preventing oxidative damage to extracellular structures. In this regard,
NOX2 has been shown to synthesize superoxide and release
it into the luminal extracellular space mostly from AEC I
[9, 60, 61]. Consistent with its important antioxidant function, polymorphisms in SOD3 are associated with reduced
lung function and chronic obstructive pulmonary disease
(COPD) [62].
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Exogenous administration of catalase has been shown to
mitigate respiratory viral infections. Intranasal catalase protected against respiratory syncytial virus (RSV) infection
[63], a virus that can induce a cytokine storm [64]. Catalase
treatment led to a signiﬁcant reduction in the levels of the
cytokines IL-1α, TNF-α, and IL-9 and the chemokines
CSCL1, CCL2, and CCL5 [63]. During the early stages of
other types of respiratory infections, increased ROS activates
the nuclear factor erythroid 2-related factor 2 (NFE2L2 commonly called Nrf2) transcriptional regulator to induce antioxidant genes such as SOD3 and catalase to protect against
the ROS-induced proinﬂammatory gene expression and subsequent cytokine storm. However, RSV infection leads to the
proteolytic degradation of Nrf2, preventing the protective
antioxidant response [6] to facilitate the cytokine storm. In
addition, catalase can be inactivated by high levels of ROS
and RNS in the lungs [65]. Inﬂuenza A virus (IAV) is another
virus that induces a cytokine storm [66]. In mice infected
with IAV, intranasal administration of the mitochondrialtargeted antioxidant, MitoTEMPO, quenched ETC-derived
ROS in the lungs to decrease proinﬂammatory gene expression, cytokine storm, and consequent mortality [67]. A similar study found that intranasal administration of a NOX2
inhibitor had similar protective eﬀects against IAV infection
in mice [68, 69]. Therefore, both mitochondria- and NADPH
oxidase-mediated increases in ROS contribute to IAV mortality. The role of NADPH oxidase in respiratory virus infections has been reviewed [9].
2.3. ROS and RNS Are Formed by the Oxidative Burst in
Phagocytes. Phagocytes release proteolytic enzymes, ROS,
and RNS into their phagosomes to mediate the killing of
endocytosed pathogens. The phagosomal oxidative burst
requires cytoplasmic NADPH as a coenzyme for
membrane-bound NADPH oxidase to produce phagosomal
superoxide (Figure 4). The iron-dependent metalloprotein
myeloperoxidase (MPO) is a component of primary granules
that fuse with the phagosome [70]. MPO catalyzes the synthesis of toxic hypochlorous acid from hydrogen peroxide
and chloride ion. Two gases, nitric oxide and CO2, are critical
for the synthesis of toxic carbonate radicals. For this to occur,
ﬁrst the superoxide radical must bind to the nitric oxide radical to form peroxynitrite, and then, peroxynitrite reacts with
carbon dioxide to form nitrosoperoxycarbonate that
degrades to the carbonate radical. Peroxynitrous acid, having
a pKa of 6.8, forms physiologically when peroxynitrite binds
to a proton and is a major source of hydroxyl radicals [71]. As
CO2 levels increase, the half-life of peroxynitrite decreases
from roughly a second down to several milliseconds [72].
The ROS and RNS that are produced during viral infection
take on speciﬁc roles as sentinels, messengers, and oxidizing
agents that determine the activity of many classes of proteins
including transcription factors [71]. Hydroxyl radicals are
short lived and function primarily as oxidizing agents. Superoxide is negatively charged and does not diﬀuse directly
across lipid bilayers, but it has been shown to be transported
by proteinaceous channels from the mitochondria to the
cytoplasm [73, 74]. Hydrogen peroxide is transported by
aquaporins across cellular membranes. The concentration
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of hydrogen peroxide in the cytoplasm is generally indicative
of the health of mitochondria, but transient increases can be
the result of signaling events. Nitric oxide is a free radical that
passes through membranes and can potentially signal to
nearby cells in its relatively short half-life. Peroxynitrous acid
can also cross cellular membranes. The half-lives and diﬀusion limits of diﬀerent types of ROS are shown in Figure 5.
The importance of this diﬀusion of ROS and RNS between
cells is that cells that lack the receptor for the virus can
attempt to mount an appropriate response to the infection.
2.4. ROS/RNS Aﬀects the Nucleotide Coenzyme Couples.
Virus-induced ROS production and cytokine storm induce
energy dysfunction and redox imbalance in host cells in the
lungs by altering the ADP/ATP, NAD+/NADH, and
NADP+/NADPH ratios that control central metabolism.
(1) ROS produced by the mitochondrial ETC damages
proximal ETC proteins resulting in decreased electron ﬂux, which increases the cellular ADP/ATP (less
ATP)
(2) The decreased ETC ﬂux also decreases the cellular
NAD+/NADH (more NADH) as the rate of NADH
hydrolysis by ETC complex I slows
(3) The increased superoxide produced from the ETC is
converted by superoxide dismutase 1 (SOD1) and
SOD2 to hydrogen peroxide. H2O2 is detoxiﬁed by
glutathione peroxidase through the conversion of
reduced glutathione (GSH) to glutathione disulﬁde
(GSSG). Increased activity of NADPH-dependent
glutathione reductase is needed to recycle GSSG to
GSH leading to an increased cellular NADP+/NADPH ratio (less NADPH). In a parallel pathway
yielding the same result, hydrogen peroxide is detoxiﬁed by peroxiredoxins. The oxidized peroxiredoxins
are then reduced by thioredoxins, and lastly, the
oxidized thioredoxins are reduced by thioredoxin

reductase using the reducing power of NADPH leading to an increased cellular NADP+/NADPH ratio
The ADP/ATP, NAD+/NADH, and NADP+/NADPH
couples control hundreds of cellular reactions. When these
levels are altered in cells during a cytokine storm, the cells
can no longer eﬀectively perform their primary functions
leading to cell dysfunction and death and to pathologies such
as ARDS.

3. Importance of Energy Metabolism in
Blunting the Cytokine Storm
In immune cells, transitioning from an inactive state to an
inﬂammatory and then to a postinﬂammatory state is accompanied by metabolic reprogramming. This assures that cells
have adequate energy and redox potential to perform their
new roles, including entering the cell cycle for propagation,
performing an oxidative burst, or undergoing regulated apoptosis rather than necrosis. The mitochondrial PDC is well
positioned to reprogram metabolism as it is the gatekeeper
of carbohydrate ﬂux into mitochondria as well as a major
regulator of cellular NAD+/NADH. When it is active, it
reduces mitochondrial NAD+, and when it is inhibited, it
redirects pyruvate metabolism to the cytoplasm where lactate
dehydrogenase reduces pyruvate by oxidizing NADH. PDC
activity, by modulating the NAD+/NADH ratio, also aﬀects
the ﬂux through glycolysis and the mitochondrial citric acid
cycle, fatty acid oxidation, and oxidative phosphorylation.
3.1. Viral Infection Leads to Mitochondrial ETC Dysfunction
and Decreased Energy Metabolism. The innate immune
response to SARS-CoV-2 begins with the cellular production
of the type I interferons α and β from plasmacytoid dendritic
cells, macrophages, and AEC II. Viral double-stranded RNA
replication intermediates stimulate TLR3 (toll-like receptor
3) leading to decreased ETC complex I gene expression
[75], decreased ETC complex I activity, and increased ETCmediated and NOX2-mediated ROS production [43–45],

8

Oxidative Medicine and Cellular Longevity

No
Peroxynitrite
Superoxide
H2O2

Superoxide diﬀusion
range depends on
the secretion of
SOD3 by AECII.

Hydrogen peroxide
will persist in the
absence of catalase

Peroxynitrite half-life
is determined by CO2
level. If there is
adaquate CO2, the
half-life is a few
miliseconds.

Peroxynitrite half-life
is determined by CO2
level. It can vary from
milliseconds to ~1
second.

Superoxide does not
leave the membrane
compartment where it
was made.
Superoxide in
mitochondria reacts
with NO to form
peroxynitrite.

Figure 5: The half-lives and diﬀusion limits of ROS/RNS.

likely through type I interferon signaling [76], which
increases proinﬂammatory cytokine production. In this
regard, treatment with TNF-α was shown to downregulate
the expression of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a master regulator of mitochondrial gene expression [77], decreasing mitochondrial
ETC function and oxygen consumption in mouse lung
AEC [8]. Downregulation of PGC-1α would likely increase
ROS production as PGC-1α also induces antioxidant
enzymes such as SOD2 and catalase [78]. Unexpectedly,
peripheral blood mononuclear cells (PBMCs) from SARS
patients were shown to have increased expression of
mitochondrial-encoded subunits of the ETC [79], which
could lead to increased ROS production due to incompletely formed ETC complexes when the nuclear-encoded
subunits are downregulated. SARS-CoV-2 RNA has been
shown to localize to mitochondria [80, 81], likely to
attempt to hide from cellular immune surveillance systems. This could partly explain how SARS-CoV-type coronaviruses have been shown to be quite eﬀective in
blocking the type I interferon β response during the initial
stages of the infection [82, 83].
3.2. Targeting the Viral-Induced Decrease in PDC Activity. In
mice infected with IAV, ATP levels greatly decreased and the
level of a negative regulator of PDC, pyruvate dehydrogenase
kinase 4 (PDK4), increased substantially. Administration of
diisopropylamine dichloroacetate (DADA), an inhibitor of
PDK4, signiﬁcantly delayed mortality from the infection
[17]. However, the infection led to severe anorexia, which

also increases PDK4 levels in some tissues such as those in
the muscle [84] and liver [85] due to increased FOXO1,
PPAR-α, and glucocorticoid receptor (GR) [86] transcriptional activity. This inactivation of PDC during starvation
likely evolved to save glucose and lactate (which is converted
back into glucose in the liver as part of the Cori cycle) for
neurons, which do not eﬃciently oxidize fatty acids. The full
extent to which the virus directly upregulated PDK4 levels is
unknown. The levels of the proinﬂammatory cytokines TNFα, IL-6, and IL-1β were shown to increase following IAV
infection [17]. As stated above, a TLR3- and type I
interferon-dependent response to viral RNA has been shown
to reduce the expression of four subunits of mitochondrial
ETC complex I [87]. This likely contributes to decreased
ATP production. DADA administration signiﬁcantly
increased pyruvate dehydrogenase (PDH) activity and ATP
levels in the skeletal muscles, heart, lungs, and liver and
tended to normalize plasma levels of glucose, lactate, free
fatty acids, and R-BHB [17]. DADA administration also suppressed the IAV-induced increase in IL-6, IL-2, IFN-α, TNFα, and IFN-γ levels, but not that in IFN-β or IL-1β [17]. PDK
inhibitors have also been shown to have protective antiinﬂammatory eﬀects. This may partly result from their eﬀects
on T lymphocytes, as proinﬂammatory Th17 cells have high
levels of PDK1 and show primarily glycolytic metabolism,
while anti-inﬂammatory Th1 and Treg cells have low PDK1
levels and show primarily oxidative metabolism. Knockdown
of PDK1 suppressed Th17 cells and increased Treg cell numbers to restore immune function in mice with experimental
autoimmune encephalomyelitis [88].
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In another study of IAV infection in mice, glucose administration during the period of anorexia following IAV infection
was found to decrease the mortality rate [89]. Glucose administration likely stimulated the insulin receptor-AKT signaling
pathway to decrease FOXO1 activation to blunt the increase
in PDK4 levels resulting from anorexia to maintain energy
generation [86]. Other activators of mitochondrial energy
metabolism, such as the peroxisome proliferation-activated
receptor-gamma (PPAR-γ) agonist pioglitazone or rosiglitazone and the AMP kinase activator, AICAR, have also been
shown to protect mouse mortality from IAV infection [90].
These compounds are all known to decrease PDK4 levels in
the muscle and liver [91]. Therefore, FOXO1 hyperactivation
may be a pathological event in mouse IAV infection as it is
induced by both increased ROS levels [92] and the anorexia
that occurs following IAV infection. A mechanism through
which antioxidant administration protects against viral infection may be through preventing FOXO1 induction of PDK4.
The use of PPAR-γ agonists to treat the cytokine storm in
COVID-19 has been reviewed [93].
Figure 3 shows the central role of PDC at the gateway
between glycolytic and citric acid cycle metabolism.

Figure 6 shows the multiple transcription factors that control
the expression of the kinases and phosphatases that regulate
PDC activity as well as controlling the expression of the three
enzymes that comprise the PDC. Figure 6 also shows that
R-BHB is catabolized into two acetyl-CoA molecules that
enter the citric acid cycle and bypass PDC inhibition. An
NADH, which fuels complex I of the ETC, is also generated during R-BHB oxidation to acetoacetate. R-BHB has
also been shown to increase PGC-1α levels [94] and mitochondrial fusion [95, 96], which are known to increase
mitochondrial energy generation. Therefore, ketone body
catabolism is a substantial source of ATP when the cytokine storm leads to the block of the mitochondrial oxidation of carbohydrate catabolites.
3.3. Viral-Induced Ca2+ Dysregulation May Lead to ATP
Decline, Osmotic Imbalance, Edema, and Restricted Lung
Volumes. There are nine major inorganic ions found intracellularly and extracellularly, Na+, K+, Ca2+, Mg2+, H+, Cl-,
HCO3-, H2PO42-, and HPO4-, which regulate plasma membrane potential and osmotic balance [99]. ATP drives the
ion pumps that provide the chemiosmotic potential to
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maintain the distribution of these ions (Figure 7), preventing
edema. The major SARS-CoV-2 spike (S) protein binds to
extracellular Ca2+ to facilitate viral fusion with host cells such
as AEC II [100] and signals for the opening of plasma membrane Ca2+ channels through a protein kinase C-α signaling
pathway, which may be triggered by ER stress [101]. The
SARS-CoV-2 envelope (E) protein is a lipidated viroporin,
which forms a cation-selective channel in the endoplasmic
reticulum that releases Ca2+ [102]. Blocking the viralinduced increase in cellular Ca2+ levels with a chelator
decreased infectivity 60-fold [100]. The increased cytoplasmic Ca2+ leads to the activation of the plasma membrane
and ER Ca2+ pumps, depleting ATP levels. Increased
cytoplasmic Ca2+ stimulates the uptake of Ca2+ into the mitochondrial matrix in a mitochondrial membrane potentialdependent manner. In the presence of high levels of ROS
caused by viral infection, the rapid uptake of Ca2+ into the
mitochondrial matrix may stimulate permeability transition
pores to open in the inner membrane [103], which uncouple
mitochondria leading to further energy depletion and cell
death. However, mammals have evolved mechanisms to use

the viral-induced increase in cytoplasmic Ca2+ as a signal to
upregulate host defenses. An increase in the cytosolic Ca2+
concentration by these mechanisms contributes to the activation of the NLPR3 inﬂammasome and elevation of IL-1β and
IL-18 [102]. Increased cellular Ca2+ levels in AEC II lead to
increased mitochondrial ETC-derived ROS and increased
ROS from NADPH oxidases DUOX1 and DUOX2, the most
abundant isoforms in AEC, through Ca2+ binding to their
EF-hand motifs [9]. DUOX2 is also upregulated at the gene
expression level by the increased interferon-β and TNF-α
produced in response to the respiratory viral infection [104,
105]. Hydrogen peroxide can diﬀuse from AEC into adjacent
cells leading to oxidative damage, energy depletion, and
osmotic imbalance. Increased cytoplasmic Ca2+ levels in airway myocytes induce constriction of the airways. Several
protein kinase C (PKC) isoforms are activated by Ca2+, and
their activation is an important contributor to bronchoconstriction [106, 107]. PKC directly targets and inhibits Kv7
K+ channels, which are important for the relaxation of airway
smooth muscle [108]. Inhibition of Kv7 channels induces
bronchial constriction [109], which can contribute to ARDS.
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The use of R-BHB as an energy source may blunt the cellular
energy deﬁcit, the increase in cytoplasmic Ca2+ levels, and the
osmotic imbalance to improve lung function.

4. High-Fat Diet Decreases the Average Time on
a Ventilator for Patients with Respiratory
Failure or ARDS
High-fat, low-carbohydrate enteral feeding of patients with
type II respiratory failure (the inability to expel CO2 at a normal rate) reduced the mean length of time on a ventilator by
40%, from 158 hours down to 96 hours, compared to patients
on high-carbohydrate, low-fat enteral feeding [110]. Arterial
blood CO2 levels, an indicator of patient respiratory distress,
decreased to 18% for patients in the high-fat group at the
time of weaning oﬀ the ventilator. The high-carbohydrate
group had an even higher partial pressure of CO2 at weaning
than at the onset of ventilation. A likely contributor to the
diﬀerence observed between the groups was the amount of
CO2 synthesized from metabolizing the diﬀerent diets. The
amount of CO2 synthesized for every molecule of oxygen
consumed is deﬁned as the respiratory exchange ratio
(RER). The RERs for catabolism of fat, glucose, and R-BHB
are 0.7, 1.0, and 0.88, respectively. A high-fat diet was also
protective in a mouse model of ventilator-induced lung
injury [111], a model of ARDS. A high-fat, lowcarbohydrate diet supplemented with ﬁsh oil, gammalinolenic acid, and antioxidants was also shown to decrease
the time on a ventilator for patients with ARDS due to sepsis/pneumonia [112], trauma, or aspiration injury; the ﬁndings may be relevant for ARDS mediated by viral infection
as well.

5. Either Ketogenic Diet or Glucose
Administration Protects against IAV
Infection in Mice
Due to the lack of published data on the eﬀects of increased
R-BHB levels on the human immune system during viral
infection, results obtained from several studies of metabolic
therapy on IAV-infected mice are described below. A shortterm ketogenic diet was shown to protect mice from IAV
infection, while racemic R- and S-1,3-butanediol (BD), an
exogenous ketone precursor, supplemented to a normal
chow diet did not [113]. A long-term ketogenic diet that
was obesogenic was shown to adversely aﬀect glucose tolerance and immune system function [114]. As described above,
glucose gavage during IAV-induced anorexia decreased
mouse mortality [89], while a more recent study showed that
glucose metabolism through the hexosamine biosynthetic
pathway stimulated a cytokine storm [89]. In the sections
below, the results from these studies will be described in more
detail and analyzed in an attempt to reconcile these ﬁndings.
The rationale will also be discussed for the consumption of a
moderately high-fat, moderate-carbohydrate, ketone estercontaining diet at the onset of viral infection,and transitioning to a moderately high-fat, low-carbohydrate, ketone
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ester-containing diet if the infection becomes severe to blunt
the cytokine storm.
5.1. A Ketogenic Diet Decreases IAV Mortality in Mice by
Activating a γδ T Cell Response. A recent study showed that
mice placed on a ketogenic diet for seven days before infection had decreased mortality from IAV [113]. The ketogenic
diet increased the number of protective IL-17-secreting γδ T
cells in the lungs. Administration of the ketone precursor BD
to mice on a chow diet did not protect the survival or lead to
the recruitment of γδ T cells to the lungs in the mice infected
with IAV, even though the R-BHB blood level was equivalent
to that of the ketogenic diet. One point raised regarding the
design of this study is that while dietary protein amount (%
w/w) was uniform between control and KD mice [115], the
micronutrient and ﬁber proﬁles were not [116]. While this
did not likely impact the conclusions of the study, it should
be a point of emphasis for future experiments.
BD administration may not have shown protection due
to a lack of improvement of the cellular redox environment
in the lungs that likely occurred during the ketogenic diet.
During times of high R-BHB oxidation in the brain, the cytoplasmic NADP+/NADPH becomes more reduced and the
cytoplasmic NAD+]/[NADH becomes more oxidized [16].
The ketogenic diet, which is very high in fat content, may
have improved the cytoplasmic redox environment, in part,
through inhibition of fatty acid synthesis, an NADPHconsuming pathway, by increasing levels of palmitoyl-CoA,
an inhibitor of fatty acid synthase activity. So, the combination of increased R-BHB metabolism and decreased fatty acid
synthesis may lead to a decrease in the cytoplasmic NADP+/NADPH ratio that may lead to the recruitment and enhanced
function of γδ T cells in the lungs, which does not occur
when R-BHB is catabolized when mice are fed a normal chow
diet. A high-fat but nonketogenic diet was shown to be ineffective in decreasing IAV-induced weight loss and mortality,
even though it increased the recruitment of IL-17-secreting
γδ T cells to the lungs. IL-17 binds to receptors on lung epithelial cells and possibly other lung cell types to increase the
expression of IL-33. IL-33 secretion leads to the recruitment
of type 2 innate lymphoid cells (ILC2s) to the lungs, where
they play a role in regulating inﬂammation and barrier function by secreting the cytokines IL-5, IL-9, IL-13, and amphiregulin. In lung tissue, the ketogenic diet upregulated
mitochondrial ETC gene expression and the expression of
the OXCT1 gene encoding SCOT (succinyl-CoA:3-ketoacid
CoA transferase), the rate-limiting enzyme for ketolysis,
suggesting that R-BHB catabolism in the lungs plays an
important role in the protective eﬀects of the ketogenic diet
against viral infection [113].
It is hypothesized that supplementation of ketone ester to
mice on a moderately high-fat diet will lead both to the
recruitment of γδ T cells to the lungs and to decreased mortality of IAV-infected mice. While one week of ketogenic diet
prior to IAV infection was shown to be anti-inﬂammatory
and decrease mouse mortality, three months of the ketogenic
diet in the absence of IAV infection increased white adipose
tissue (WAT) inﬂammation, decreased γδ T cell recruitment
to the WAT, and led to obesity and glucose intolerance [114].
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Therefore, current evidence from mouse studies where the
animals were fed obesogenic ketogenic diets suggests that
only short-term ketogenic diets will activate γδ T cells to
boost immune function [114]. However, another research
group identiﬁed a ketogenic diet of a diﬀerent composition
that was shown to induce weight loss in mice [117]. The dietary components responsible for the diﬀerent eﬀects on
weight are currently unknown, although the leptogenic diet
contained only half as much protein and used lard, butter,
and vegetable oil as fat sources, while the obesogenic diet
used hydrogenated soybean oil as the fat source [114, 117].
Future studies are needed to determine if a ketogenic diet that
induces weight loss can provide long-term preservation of
the protective γδ T cell response to provide long-term antiviral immunity.
It is also hypothesized that increased R-BHB levels
improve cellular energy metabolism and redox status to
enhance fatty acid beta-oxidation to overcome the metabolic
inﬂexibility mediated by PDC inhibition. R-BHB is known to
inhibit adipose tissue lipolysis [118], so a high-fat diet may be
needed, along with exogenous ketones, to provide suﬃcient
fatty acid beta-oxidation for increased metabolic ﬂexibility
to overcome a cytokine storm. The initiation of this diet in
humans for COVID-19 poses challenges because it may take
many days to adapt to a ketogenic diet to fully upregulate the
expression of genes for ketogenesis, ketolysis, and fatty acid
oxidation. Proinﬂammatory cytokines also inhibit ketogenesis [119]. In addition, starting a ketogenic diet, also called
ketoinduction, may be accompanied by ﬂu-like symptoms
[120–122] that may limit its application to COVID-19
patients. However, studies could be performed to determine
the ability of COVID-19 patients to tolerate a ketogenic diet
supplemented with exogenous ketones, to attempt to
decrease the early adverse eﬀects of the diet that likely result
from decreased energy production when glucose levels
initially decline [122]. If well tolerated, further studies determining the ability of this diet to activate a protective immune
response could follow.
Further experiments are needed to delineate the molecular mechanisms involved if R-BHB precursors such as ketone
esters are to be used for the treatment of IAV and SARSCoV-2 infections. To test the eﬀectiveness of exogenous
ketone administration on IAV infection, mice could be supplemented with or without a ketone ester and fed a moderately high-fat, moderate-carbohydrate diet or a moderately
high-fat, low-carbohydrate diet or a control chow diet, and
weight loss and mortality could be monitored following
IAV infection. As explained in more detail below, glucose
(from carbohydrate metabolism) stimulates important proinﬂammatory antiviral functions early in infection [123],
but these proinﬂammatory actions also increase the cytokine
storm late in infection [124]. So, it is unknown which of these
eﬀects will predominate to aﬀect mortality in the presence of
high R-BHB levels. It is hypothesized that the moderately
high-fat, moderate-carbohydrate, ketone ester-containing
diet will provide the most metabolic ﬂexibility to stimulate
host cell defense mechanisms. This ﬂexibility should be able
to preserve energy metabolism and redox status to boost
immune function to decrease IAV titer in the lungs. How-
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ever, the moderately high-fat, low-carbohydrate diet with
ketone ester will likely show a stronger ability to blunt the
cytokine storm, as increased glucose and insulin levels have
recently been shown to block an important antiinﬂammatory action of R-BHB [125].
5.2. Anorexia following IAV Infection in Mice Increases
Mortality That Is Greatly Blunted by Gavage of Glucose, but
Not Fat or Protein. As alluded to earlier, mice became
anorexic following IAV infection and the anorexia contributed to their mortality, as glucose gavage was able to decrease
the mortality. In that study, gavage of olive oil (fat) or casein
(protein) did not decrease mortality [89]. The proinﬂammatory cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, several of which increase following IAV infection, have been
shown to suppress appetite [126]. So, it is likely that administering a ketogenic diet simply decreased cytokine levels,
allowing for an increase in the amount of food consumed
to decrease the mortality of the mice. Consistent with this
interpretation, mice on the ketogenic diet lost less weight following infection than the chow-fed mice [113]. These results
may be applicable to SARS-CoV-2 infection, as 40% of
COVID-19 patients reported lack of appetite as a symptom
[127]. A major research question that arises from these studies is whether a twice-daily isocaloric gavage of ketone ester
starting on the day of infection, to mimic the protective eﬀect
of the twice-daily gavage of glucose [89], can protect mice fed
a chow diet from IAV infection. This hypothesis is reasonable given that the protective ketogenic diet was composed
of roughly 90% fat, 10% protein, and only 0.1% carbohydrate
[113]. So, the carbohydrate content of the diet was likely too
low to provide adequate glucose for protection, and gavage of
fats or protein was unable to provide protection [89]. The
ineﬀectiveness of the ketone precursor BD against IAV infection [113] suggests that ketone ester alone may be ineﬀective
and that gavage of fat and ketone ester together as a cotherapy, to better mimic a ketogenic diet, may be needed for
protection. Experiments probing possible additive or synergistic eﬀects among glucose, ketone ester, and fats on
increased survival during IAV infection in mice would
provide valuable insights relevant to the protection against
a cytokine storm in humans.

6. Glucose Metabolism through the Hexosamine
Biosynthesis Pathway Protects against Viral
Infection but Stimulates the Cytokine Storm
So, how may glucose gavage of mice during viral-induced
anorexia decrease mortality from IAV infection? Glucose
has been shown to stimulate a proinﬂammatory antiviral
response through increased ﬂux through the hexosamine
biosynthesis pathway. The increased ﬂux increases levels of
the pathway end product UDP N-acetylglucosamine (UDP
GlcNAc), which increases the O-GlcNAcylation of the antiviral protein MAVS to increase its function (Figure 8(c)) [123].
The SARS virus synthesizes the NPS15 protein, which
partially inhibits MAVS function to block host antiviral signaling [128]. In addition, viral nucleic acids and type I interferon signaling in macrophages lead to the increased
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Figure 8: Proinﬂammatory signaling that occurs during viral infection and mechanisms through which R-BHB inhibits this signaling. (a) The
ACE system. (b) The mechanism by which R-BHB inhibits the NLRP3 inﬂammasome is unknown. Four possible mechanisms are shown. (c)
The hexosamine biosynthesis pathway is required to initiate an eﬀective antiviral innate immune response, but its increased activity can also
stimulate a cytokine storm. Abbreviations: 6PGDL: 6-phosphonoglocono-D-lactone; 6PG: 6-phosphogluconate; ACE2: angiotensinconverting enzyme 2; ACE: angiotensin-converting enzyme; ANG (1-9): angiotensin (1-9); ANG (1-7): angiotensin (1-7), a vasodilator;
ANG II: angiotensin II, a vasoconstrictor; ANG III: angiotensin III, a metabolite of ANG II; BRCC3: Lys-63-speciﬁc deubiquitinase
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expression of the glycolytic activator 6-phosphofructose-2kinase and fructose-2,6-bisphosphatase (PFKFB3), which
are required for the increased engulfment of viral-infected
cells [129]. Surprisingly, mortality from IAV infection in
mice has been linked with viral induction of an ER stressinduced apoptotic pathway in the brain [89]. Both glucose
and R-BHB are important protective fuels for neurons,
potentially reconciling ﬁndings of how either glucose or a
ketogenic diet is protective. In addition, high glucose levels
may compensate for the energy and redox crisis occurring
as a result of viral-induced PDC inhibition by increasing ﬂux
through glycolysis for the synthesis of ATP and by increasing
ﬂux through the pentose phosphate pathway (PPP) for the
synthesis of NADPH. Glucose ﬂux through the hexosamine
biosynthesis pathway has been shown to stimulate the cytokine storm during IAV infection in mice by increasing the
O-GlcNAcylation of the transcriptional regulator IRF5,
which increases its activity to stimulate proinﬂammatory
cytokine production (Figure 8(c)) [124]. This may explain
in part why people with diabetes who are infected with
SARS-CoV-2 have a higher mortality rate [130]. Therefore,
inhibitors of IRF5 or inhibitors of O-GlcNAcylation, such
as OSMI-1, are potential treatments for the SARS-CoV-2
cytokine storm. Ketone ester treatment has been shown to
decrease blood glucose levels [131, 132], which would likely
decrease ﬂux through the hexosamine biosynthesis pathway
in immune cells to decrease cytokine production.

7. Molecular Mechanisms through Which RBHB Inhibits Inflammation
Monocarboxylate transporters are expressed in AEC II [133],
allowing the entry of R-BHB into the cytoplasm. However,
these cells have low expression of ketolytic enzymes, so they
may be unable to substantially catabolize the R-BHB produced
from the consumption of exogenous ketones [134]. However,
a ketogenic diet was shown to increase the expression of ketolytic genes in the lungs [113], so it is possible that these
enzymes can be induced in AEC II and are responsible, in part,
for the protective eﬀects of the ketogenic diet. Even if R-BHB is
not catabolized by AEC II, the presence of R-BHB in AEC II
may still greatly protect these cells through signaling pathway
activation, through enzyme inhibition, and through gene
expression pattern alteration as described in detail below.
7.1. R-BHB Inhibition of the NLRP3 Inﬂammasome May
Depend upon the Metabolic State of the Cell. R-BHB inhibits
the NLRP3 inﬂammasome [135]. S-BHB, the enantiomer of
R-BHB, was also eﬀective, but not butyrate. The molecular
target through which R-BHB and S-BHB inhibit the inﬂammasome is still unknown, but treatment decreased cellular
K+ eﬄux and reduced inﬂammasome activator ASC (apoptosis-associated speck-like protein containing a CARD)
oligomerization (Figure 8(b)). R-BHB-mediated inhibition
of the inﬂammasome did not require ketone body catabolism, since siRNA of the ketolytic enzyme SCOT did not
block inhibition. Inﬂammasome inhibition was also shown
to be independent of the eﬀects of R-BHB on GPR109A Gprotein-coupled receptor (GPCR) signaling and histone
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acetylation. In addition to immune cells, several types of
epithelial cells express the genes for a functional NLRP3
inﬂammasome; R-BHB likely protects AEC II from a cytokine storm in part through this mechanism [136]. Recently,
high insulin or high glucose levels were shown to decrease
R-BHB-mediated inhibition of the NLRP3 inﬂammasome
in macrophages in vitro, and 2-deoxyglucose, a glycolysis
inhibitor, was shown to potentiate NLRP3 inﬂammasome
inhibition by R-BHB [125]. Therefore, the metabolic state
of the cell appears to inﬂuence the eﬀect of R-BHB on the
NLRP3 inﬂammasome.
Somewhat surprisingly, a single dose of exogenous
ketones was shown to increase inﬂammasome activation in
LPS-stimulated blood cells and increase plasma IL-1β and
IL-6 levels of healthy young people after a 10-hour overnight
fast [137]. The mechanisms remain unknown, but increased
levels of these proinﬂammatory markers may have been
due to an R-BHB-mediated increase in NADPH levels stimulating NADPH oxidase activity to increase ROS levels and
possibly also due to increased mitochondrial ROS production
that occurs when R-BHB and glucose are oxidized simultaneously, as increased ROS stimulates NLRP3 inﬂammasome
activity [138]. However, a follow-up study by the same group
administering exogenous ketones to obese subjects found no
diﬀerence in inﬂammasome activity and the levels of many
proinﬂammatory markers but a slight decrease in IL-1β
and TNF-α levels in the exogenous ketone-treated group
[139]. In a study of well-trained cyclists, acute BD administration was shown to slightly increase interferon-gamma
expression in PBMCs, while anti-inﬂammatory cytokine
expression was unaltered [140]. Overall, the lack of NLRP3
inﬂammasome inhibition and the lack of strong antiinﬂammatory eﬀects of exogenous ketones in the above
human studies are likely due to the metabolic state of the subjects when the exogenous ketones were administered. It is
possible that the glucose levels and insulin levels were too
high to allow R-BHB to inhibit the inﬂammasome [125].
SARS-CoV-2 infection can cause ketosis and ketoacidosis, and these patients with high blood R-BHB levels had longer hospitalization and an increased mortality rate [141].
Also, COVID-19 patients with type I or II diabetes mellitus
(DM) have an increased risk of developing diabetic ketoacidosis (DKA), which contributes to mortality [142]. The
molecular basis for these ﬁndings is not entirely clear as
ketone bodies do not directly cause DKA. Recent ﬁndings,
however, indicate that the increased glucose levels in mouse
models of diabetes can decrease the expression of the ketolytic genes R-BHB dehydrogenase (BDH1) and OXCT1 in the
heart [143]. If this also occurs in other tissues such as skeletal
muscle, it would likely lead to increased blood ketone levels.
Expressing an exogenous transgene to increase OGlcNAcylation in the mice further decreased BDH1 levels
demonstrating a role for the hexosamine biosynthetic pathway in this downregulation of ketolytic gene expression.
The SCOT enzyme (OXCT1 gene product) was shown to
be directly modiﬁed by O-GlcNAcylation. Therefore, administration of an O-GlcNAcylation inhibitor together with
exogenous ketones to diabetic patients with COVID-19
may be beneﬁcial to prevent decreased ketolysis and DKA.
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Multiple factors may be contributing to acidosis in
COVID-19 patients. Respiratory acidosis occurs due to a
buildup of carbon dioxide in the body, while lactic acidosis
occurs due to mitochondrial ETC dysfunction or PDC inhibition. R-BHB metabolism, unlike glucose metabolism, does
not raise the levels of lactic acid and may even decrease acidosis by lowering the rate of glycolysis and lactic acid synthesis. Diﬀerential diagnosis and treatment of acidosis have been
reviewed [144]. Consumption of a ketone ester has been
shown to lower glycemic response in both healthy and obese
people [131]. Fatty acid lipolysis in white adipose tissue is
inhibited by ketones [118], so in most cases, exogenous
ketones will inhibit the synthesis of endogenous ketones.
Before insulin was available, a ketogenic diet that limited carbohydrates to ≤10 g/day was a commonly used eﬀective therapy for type I diabetes [145]. During DKA, there are
imbalances in the levels of glucagon and insulin and elevation
of the stress hormones epinephrine, cortisol, and growth hormone. These changes can be triggered by a stressful event
such as COVID-19. Therefore, care would need to be taken
in administering exogenous ketones in a clinical trial for
COVID-19. Coadministration of sodium bicarbonate may
also be beneﬁcial for diabetic COVID-19 patients to buﬀer
changes in blood pH. In this regard, a recent study showed
that cyclists administered ketone ester had a 20% decrease
in blood bicarbonate levels and a slight decrease in blood
pH, while blood R-BHB levels rose to 2-3 mM. Administering bicarbonate together with ketone ester prevented these
alterations in the blood and increased blood R-BHB levels
another 0.5-0.8 mM, and this resulted in a 5% increase in
power output [146]. If diabetics are to be included in a
COVID-19 trial testing the eﬀects of exogenous ketones,
the pH of arterial blood gas (ABG) and the blood levels of
ketones would need to be monitored by experts in managing
DKA to identify early-stage ketoacidosis so that interventions
according to best practices [147] could be implemented. To
avoid risks, patients with naturally high ketone levels should
avoid exogenous ketones, so DKA may be an exclusion factor
in trials. But ultimately, a clinical trial will likely be necessary
to determine the eﬀects of exogenous ketone consumption or
a ketogenic diet on COVID-19 in both diabetic and nondiabetic patients.
The lack of protective eﬀects of high R-BHB levels under
certain metabolic conditions is likely due to the same underlying molecular mechanism that prevented supplementation
with the ketone precursor BD from preventing mortality in
IAV-infected mice [113]. A protective anti-inﬂammatory
γδ T cell response was likely not initiated in these studies.
In the studies with exogenous ketones, this was likely due
to the acute nature of the exogenous ketone treatment and
to the lack of the high-fat, low-carbohydrate diet that may
be necessary to initiate this protective anti-inﬂammatory
response. However, there are several other potential mechanisms that may have also prevented the acute ketone ester
treatment from inﬂuencing the activation state of the inﬂammasome. For example, a 24-hour fast in human subjects has
been shown to lead to NLRP3 inﬂammasome inactivation,
due to increased mitochondrial NAD+/NADH activating
the NAD+-dependent SIRT3 protein deacetylase to decrease
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ROS production [148]. Therefore, the 10-hour overnight fast
may have led to a partial inhibition of NLRP3 inﬂammasome
activity so that ketone ester treatment was unable to decrease
the activity any further. It is also possible that at least ﬁve
days of a moderately high-fat, low-carbohydrate diet with
exogenous ketone treatment may be needed to show large
anti-inﬂammatory eﬀects, as it was shown to take ﬁve days
to fully upregulate the activity of the fatty acid betaoxidation system after initiating a ketogenic diet [149, 150].
7.2. R-BHB Functions as a Histone Deacetylase Inhibitor to
Decrease Inﬂammation. R-BHB was shown to be a class I
and IIa histone deacetylase (HDAC) inhibitor
(Ki = 2 − 5 mM) that induced expression of several antioxidant genes and the transcriptional regulator FOXO3a
(Figures 9(a) and 9(b)) [151]. Administration of the other
HDAC inhibitors, butyrate or trichostatin A, showed antiinﬂammatory eﬀects on lung ILC2s, while adding both compounds together showed no additive beneﬁt [152]. This
suggested that HDAC inhibition is a protective mechanism
through which R-BHB and the ketogenic diet prevent lung
inﬂammation. There is a nuclear pool of PDC that contributes to acetyl-CoA synthesis for histone acetylation [153].
PDK1 also shows a partial nuclear localization [154], so the
upregulation of PDK1 expression during viral infection could
disrupt nuclear histone acetylation, which could be restored
by HDAC inhibitors such as R-BHB.
In studies with macrophages, butyrate was shown to
function as an HDAC inhibitor to decrease IL-6, IL-12, and
nitric oxide levels, but not TNF-α or MCP-1 levels [155]. In
a co-culture model of RAW264.7 macrophages and 3T3-L1
preadipocytes, addition of butyrate decreased the production
of TNF-α, MCP-1, and IL-6 and decreased NF-κB expression
in the macrophages [156]. Another study found that HDAC
inhibition decreases NF-κB transcription, which may be
responsible for the anti-inﬂammatory eﬀects [157]. Therefore, increasing R-BHB levels will likely lead to similar antiinﬂammatory eﬀects on lung macrophages to dampen a
cytokine storm, although butyrate has been reported to be a
superior HDAC inhibitor compared to R-BHB in some cell
types such as myotubes and endothelial cells [158]. This
decreased eﬃcacy of R-BHB as an HDAC inhibitor in some
cell types may result from diﬀerent rates of transport into
the cell or into the mitochondrial matrix, diﬀerent rates of
R-BHB oxidation, or diﬀerent endogenous nuclear histone
acetyltransferase or HDAC activities. Dietary therapies that
increase both butyrate and R-BHB levels may have additive
anti-inﬂammatory eﬀects [159]. The antibacterial eﬀect of
butyrate on intestinal macrophages was shown to be due to
HDAC3 inhibition, not GPR109A signaling. HDAC3 inhibition led to a decreased rate of glycolysis and increased ﬂux
through the PPP increasing AMP levels and AMP kinase
activity and decreasing mTOR activity to stimulate autophagy [160]. In the lung, butyrate inhibition of the class IIA
HDAC, HDAC7, decreased bacterial-induced inﬂammation
[161]. During infections, mitochondrial damage leads to the
oxidation and release of the inner membrane phospholipid
cardiolipin, leading to PPAR-gamma SUMOylation and
recruitment of HDAC3 to the promoter of IL-10, an anti-
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inﬂammatory cytokine, to decrease gene expression. Gene
expression of TNF-α was unaﬀected, so increased inﬂammation was observed. Butyrate administration increased IL-10
gene expression to normalize the level of inﬂammation
[162]. Coronaviruses have been shown to increase the oxidation of phospholipids, which stimulate toll-like receptor 4
(TLR4) signaling on macrophages, leading to cytokine production and acute lung injury [163], so HDAC inhibition
with R-BHB appears to be a viable treatment to decrease
cytokine levels and inﬂammation.
7.3. R-BHB Binds to the GPR109A GPCR to Stimulate AntiInﬂammatory Signaling. The GPR109A (hydroxycarboxylic
acid receptor 2 (HCA2), expressed from the HCAR2 gene)
GPCR is bound and activated by R-BHB (EC50 of 0.7 mM
[118]), S-BHB, or butyrate and is expressed in the lung and
many types of epithelial cells, macrophages, neutrophils,
and dendritic cells, but not in B or naïve T lymphocytes
[164]. However, GPR109A was shown to play a role in the
expansion of CD4+ and CD8+ T cells [165]. The expression
pattern of GPR109A suggests that it could play a role in the
protective eﬀects of the ketogenic diet against IAV infection
[113]. GPR109A has been shown to be activated by Zika virus
infection and protect cells by inhibiting viral replication
[166]. A major mechanism through which GPR109A signaling exerts its anti-inﬂammatory eﬀects is through suppressing the activation of the transcriptional regulator nuclear
factor-kappa B (NF-κB) [167], required for the transcription
and secretion of several proinﬂammatory cytokines [168].
Studies with GPR109A-knockout mice have identiﬁed
GPR109A signaling as essential for the increase in thermogenesis induced by its ligands [169]. Consistent with this,
GPR109A-knockout mice were obese, showing hepatic steatosis due to upregulation of enzymes of fatty acid synthesis
(ACC1 and fatty acid synthase (FAS)) and downregulation
of enzymes of fatty acid oxidation (CPT-1α). PPAR-α, the
master regulator of ketogenesis, was decreased in the liver,
while PPAR-γ, the master regulator of adipogenesis, was
increased in WAT. So, it is likely that stimulation of
GPR109A plays an important role in the induction of fatty
acid beta-oxidation and weight loss induced by the ketogenic diet. Macrophages and dendritic cells from
GPR109A-deﬁcient mice were defective in inducing naïve
T cells to diﬀerentiate into Treg cells and IL-10-producing
T cells [170]. Lack of GPR109A also decreased the expression of IL-18 [170]. GPR109A signaling has been shown
to be protective by activating the Nrf2 transcriptional regulator through an AMP kinase signaling pathway to decrease
oxidative stress [171]. GPR109A was also shown to play an
important role in maintaining epithelial barrier function
during bacterial sepsis [172], so it may play a similar role
during viral infection.
7.4. R-BHB May Stimulate the Expression of the LL-37
Antiviral Peptide and Protect It from Inactivation. Cathelicidins are a class of antimicrobial host defense peptides. LL37 is one of two human cathelicidins and released by
bronchial epithelial cells, macrophages, and neutrophils as
part of the innate immune response against respiratory viral
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infections [173]. LL-37 has many functions, including binding to nucleic acids, strengthening the viral RNA-induced
TLR3 signaling response to increase type I interferon production [174], stimulating inﬂammasome activation [175], and
reducing viral load and virion release [176, 177]. The peptide
has both proinﬂammatory and anti-inﬂammatory properties
[178], but the anti-inﬂammatory properties may predominate in the lungs as LL-37 administration decreased the
expression of the proinﬂammatory cytokines IL-8 and IL-6
and the chemokine CCL5 in response to respiratory viral
infection [179]. Respiratory viral infection increases the
expression of peptidyl arginine deiminase 2 (PAD2) in the
lungs. This class of enzymes catalyzes the removal of a positively charged amino group from protein arginine to form
citrulline, through a process called citrullination. LL-37 has
ﬁve arginine residues essential for its antiviral function,
which are targets of PAD2 function following the viralinduced increase in PAD2 expression in the lungs [179].
Increased levels of NADPH decrease the catalytic activity of
peptidyl arginine deiminases to limit LL-37 citrullination
[180, 181]. HDAC inhibitors such as butyrate have been
shown to increase the expression of LL-37 [182] to decrease
pathogen infection [183]. Therefore, R-BHB may mitigate
respiratory virus infection both by increasing LL-37 levels
and by increasing NADPH levels [16] that protect LL-37
from inactivation.
7.5. Cortisol Is Transiently Increased in Plasma by a Ketogenic
Diet and Its Level in Tissues Is Regulated by Redox-Sensitive
Coenzyme Ratios. Cortisol, an adrenal gland-secreted hormone, has anti-inﬂammatory properties through activation
of the glucocorticoid receptors. Subjects on either a ketogenic
diet [184, 185] or a severe calorie restriction diet [186] show
transient increases in cortisol levels. In mice, seven days of
ketogenic diet led to the transcriptional activation of targets
of the glucocorticoid receptor [113]. If this transient increase
in cortisol levels that occurs in humans also occurs in mice on
the ketogenic diet, the increased cortisol levels may contribute to the blunting of the cytokine storm in animals that were
fed the ketogenic diet for a week before IAV infection [113].
Mice that were fed the ketogenic diet for three months
showed increased inﬂammation, which could have been in
part due to the return of cortisol to baseline levels [114].
As may be expected due to the function of cortisol as a
stress hormone, when healthy subjects were administered
ketone ester in nonketogenic states, no change in cortisol
levels was observed [22, 187]. In peripheral tissues, such as
the lungs, the level of cortisol is regulated by the 11βhydroxysteroid dehydrogenase (11β-HSD) system consisting
of the two enzymes, 11β-HSD1 and 11β-HSD2. The conversion of cortisone to the active steroid hormone cortisol is catalyzed by NADPH-dependent 11β-HSD1 [188], while the
reverse reaction that regenerates the precursor cortisone is
catalyzed by the NAD+-dependent 11β-HSD2 enzyme
(Figures 1 and 2). Therefore, the level of active cortisol in tissues is under tight control by the NAD+/NADH and
NADP+/NADPH redox ratios. Ketone ester treatment has
been shown to normalize these coenzyme ratios in diseased
mouse tissue [16]. Corticosteroid hormone administration
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has been used in an attempt to blunt the cytokine storm in
several human respiratory viral infections [28]. To be successful, this therapy must be administered at the appropriate
time late in the infection cycle to allow the immune system to
ﬁrst mount a proper antiviral response. Since identifying the
appropriate timeframe for treatment for diﬀerent patients is
challenging, glucocorticoid therapy has been largely unsuccessful and may have even contributed to detrimental patient
eﬀects when used to treat inﬂuenza infection [189]. However,
emerging data suggest that short-term dexamethasone treatment may be beneﬁcial for SARS-CoV-2 infection [190], and
dexamethasone treatment was shown to decrease the mortality of patients with severe SARS-CoV-2 infection who were
placed on a ventilator [191]. Increasing R-BHB levels,
together with a moderately high-fat diet, may be able to
stabilize nucleotide coenzyme ratios to allow virally infected
tissue to increase endogenous cortisol levels at the appropriate time in the infection cycle to decrease inﬂammation and
blunt the cytokine storm.
7.6. R-BHB May Blunt Renin-Angiotensin Proinﬂammatory
Signaling through HDAC Inhibition. SARS-CoV-2 virions
bind to angiotensin-converting enzyme 2 (ACE2) receptors
[192, 193] on the surface of host cells, such as AEC II, as a
ﬁrst step in viral entry [194]. The level of ACE2 receptors
decreases during aging and may also decrease due to endocytosis during SARS-CoV-2 infection [195, 196]. In this reninangiotensin signaling system, renin catalyzes the conversion
of angiotensinogen into angiotensin 1 (ANG I).
Angiotensin-converting enzyme 1 (ACE1) then catalyzes
the conversion of ANG I into angiotensin II (ANG II), which
binds to the AT1R receptor leading to vasoconstriction and
proinﬂammatory, prooxidative, and proﬁbrotic eﬀects leading to tissue injury. ACE2 is normally able to blunt these
eﬀects by cleaving ANG I and ANG II into peptides that bind
to the AT2R and MasR receptors that signal for vasodilation
and anti-inﬂammatory, antioxidative, and antiﬁbrotic eﬀects
leading to tissue protection (Figure 8(a)) [197–201].
Increased levels of ANG II stimulate the synthesis of the proinﬂammatory cytokines IL-6, IFN-γ, TNF-α, and IL-1β
[202], but also the anti-inﬂammatory cytokines TGF-β1
and IL-10, which may induce M2 macrophage polarization
[203] and prevent the γδ T lymphocyte activation needed
to initiate the antiviral immune response [204]. Butyrate
and other HDAC inhibitors have been shown to decrease
the expression of angiotensinogen, renin, and AT1R to block
this proinﬂammatory signaling [205, 206]. Therefore, the use
of exogenous ketones could lead to a balancing of signaling
through the diﬀerent arms of the renin-angiotensin system
when proinﬂammatory signaling through ANG II predominates such as in aged individuals and subjects infected with
SARS-CoV-2.
7.7. R-BHB Has Diﬀerent Eﬀects on Proinﬂammatory
Cytokine Production in Diﬀerent Cell Types. The eﬀects of
R-BHB on proinﬂammatory cytokine production in diﬀerent
cell types can vary greatly. For example, R-BHB, when given
to isolated macrophages challenged with Streptococcus
uberis, was shown to increase the expression of IL-1β and
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IL-10 and the chemokines CXCL2 and CCL5 but had no
eﬀect on the expression of TNF-α and TGF-β [207]. In
another report using isolated M1 peritoneal macrophages,
R-BHB was shown to decrease the expression of IL-15, but
not IL-1β, TNF-α, or IL-6 [208]. In calf hepatocytes, RBHB was shown to increase NF-κB activity and the expression of IL-1β, TNF-α, and IL-6 [209], while ketosis had
similar eﬀects in the liver of cows [210]. The absence of ketolytic enzymes and presence of ketogenic enzymes in the
liver may contribute in part to the proinﬂammatory
response. In LPS-stimulated BV-6 microglial cells, R-BHB
was shown to decrease NF-κB activation and the expression
of TNF-α, IL-1β, and IL-6 [211]. When infused into the rat
brain prefrontal cortex for 21 days in a model of depression
(chronic unpredictable stress paradigm), R-BHB was shown
to prevent the increase in TNF-α and the decrease in corticosterone brought about by the depression-inducing stress
[212]. Peripheral injection of R-BHB was also able to
decrease IL-1β and TNF-α levels in the hippocampus of
rats in this depression model [213]. In bovine aorta endothelial cells stimulated with LPS, R-BHB was shown to
decrease the expression of TNF-α and interferon [214].
The diﬀerent results in diﬀerent cell types and conditions
clearly indicate that more research needs to be done to
understand the complex regulation of cytokine production
by R-BHB.

8. Molecular Mechanisms through Which RBHB Restores Redox Balance
8.1. Activation of FOXO Transcriptional Regulators and
Sirtuin Deacetylases. A major mechanism through which RBHB restores metabolism and redox balance is through epigenetic regulation of gene expression by increasing histone
beta-hydroxybutyrylation (Figure 9(c)) and inhibiting class
I and IIa histone deacetylases (HDACs) to increase histone
acetylation. Transcription factors and coactivators such as
FOXO1 [215, 216], FOXO3a [151], and PGC-1α [217] are
induced. Complexly, HDAC inhibitors can also lead to
increased acetylation of FOXO1, which reduces its activity
at the promoters of genes for gluconeogenic enzymes in the
liver to decrease blood glucose levels [218]. This is likely beneﬁcial for inhibiting the cytokine storm as discussed above.
These transcriptional regulators increase mitochondrial
ETC gene expression to help restore the NAD+/NADH. They
initiate an antioxidant gene expression program together
with the induction of PPP enzymes [219, 220] to restore the
NADP+/NADPH.
In tissues such as liver, increased R-BHB levels lead to
HDAC inhibition at the FOXO1 promoter and increased
gene expression decreasing proinﬂammatory cytokine
expression [216]. AMP kinase [221] and NAD+-dependent
SIRT1 deacetylase [222] enzymes also act on FOXO1 to
increase its activity. Insulin signaling through the AKT pathway inhibits FOXO1 activity [223]. The anti-inﬂammatory
action of FOXO1 may be due in part to its activity in lung
macrophages where it binds to IRF4 and stimulates the M2
state [224]. However, in tumor-localized macrophages,
FOXO1 has been shown to stimulate the proinﬂammatory
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M1 state and IL-1β production [225]. So, the eﬀects of
FOXO1 on macrophage function appear to be dependent
upon the environmental conditions. Increasing NAD+ levels
in the cytoplasm activates SIRT2 to deacetylate glucose-6phosphate dehydrogenase (G6PD) to increase PPP ﬂux and
NADPH production [226], linking the ratios of the pyridine
nucleotide coenzyme couples. SIRT2 also deacetylates the
inﬂammasome, inhibiting its function [227], while SIRT3
function also inhibits inﬂammasome activity by decreasing
mitochondrial ROS levels [148]. Increased nucleocytoplasmic NAD+ level also increases the activity of SIRT1, which
deacetylates PGC-1α to stimulate mitochondrial ETC function [228] leading to increased mitochondrial NAD+/NADH.
The increased mitochondrial NAD+/NADH activates mitochondrial SIRT3 to deacetylate and activate mitochondrial
SOD2 [229], isocitrate dehydrogenase 2 (IDH2) [230], and
the 39 kD subunit of ETC complex I [231] to decrease ROS
levels and decrease the mitochondrial NADP+/NADPH.
The decreased mitochondrial NADP+/NADPH maintains
reduced mitochondrial GSSG/GSH to prevent the glutathionylation of ETC complex I and the oxidation of cardiolipin that decrease complex I activity and decrease the
matrix space NAD+/NADH [232]. Other important genes
induced by the FOXO1 transcriptional regulator to restore
metabolism and decrease inﬂammation and ROS production include GPR109A, lactate dehydrogenase B (LDHB),
thioredoxin 2 (TXN2), PEPCK1, and the NAD+ synthesis
genes NAMPT and NMNAT2 [233].
8.2. Increased Expression of PGC-1α and ERR-α. PGC-1α and
ERR-α (estrogen-related receptor-α), a binding partner of
PGC-1α involved in the induction of mitochondrial ETC
gene expression [234], are the transcriptional regulators that
are known to induce OXCT1 gene expression in myotubes to
increase the levels of its gene product SCOT (Figure 9(f))
[235]. ERR-α, which is widely expressed, is also required for
adipose tissue thermogenesis [236] and is induced by fasting,
calorie restriction, cold exposure, and exercise [237, 238].
The ketogenic diet has been shown to increase PGC-1α levels
in muscle [239], neurons [95], and brown adipose tissue
[240]. These data suggest that ERR-α and PGC-1α are likely
the transcriptional regulators that induce OXCT1 and ETC
gene expression in the lungs during the ketogenic diet to
increase ketolysis and mitochondrial biogenesis [113].
SCOT activity has been shown to be decreased by tyrosine
nitration [241] and increased by tryptophan nitration [242].
SCOT activity was also inhibited by acetylation and activated by SIRT3-mediated deacetylation [243]. High-fat
diets can decrease PGC-1α levels in the liver, decreasing
its suppression of NF-κB and leading to increased cytokine
production [244]. Contrary to this result, a relatively highfat diet in the presence of ketone ester was shown to
increase PGC-1α levels and mitochondrial function in
brown adipose tissue to stimulate thermogenesis [94, 245].
Therefore, the consumption of ketone ester may reverse
the eﬀects of a high-fat diet on PGC-1α expression in some
tissues to stimulate fatty acid oxidation and prevent the
accumulation of fat in tissues that is associated with negative health outcomes.
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8.3. Metabolic Enzymes, Redox Shuttles, and Mitochondrial
Uncoupling Can Restore the NAD+/NADH and
NADP+/NADPH Ratios. Once the viral- and cytokine
storm-induced changes in the mitochondrial NAD+/NADH
have been partially restored through R-BHB-mediated signaling, enzyme inhibition, and upregulation of gene expression, the NAD+-dependent BDH1 enzyme can more
eﬀectively catalyze the conversion of R-BHB to acetoacetate.
Acetoacetate is then metabolized to acetoacetyl-CoA,
which is metabolized into two molecules of acetyl-CoA.
As mentioned above, this pathway of acetyl-CoA synthesis
becomes especially important under conditions of viral
infection because PDK4 expression is upregulated leading
to PDC inhibition.
8.3.1. Nicotinamide Nucleotide Transhydrogenase. Nicotinamide nucleotide transhydrogenase (NNT) is an enzyme that
uses energy from the mitochondrial inner membrane proton gradient to synthesize NADPH and NAD+ from
NADP+ and NADH. NNT gene expression is likely induced
by FOXO3a, since there are binding sites for FOXO3a in
the NNT promoter [233] and since the C. elegans NNT
homolog nnt-1 is induced by the C. elegans FOXO homolog
daf-16 [246, 247]. NNT activity is likely high during times
of mitochondrial ETC dysfunction, such as during a cytokine storm, as decreased mitochondrial NAD+/NADH and
increased mitochondrial NADP+/NADPH stimulate NNT
function in the normal NADPH-synthesizing and NADHhydrolyzing direction.
8.3.2. The Citrate-Pyruvate Shuttle and Other Mitochondrial
Shuttles Modulate Cytoplasmic and Mitochondrial Redox
Status. Recent evidence suggests that when glucose levels
and PPP activity are low, serine and glycine are catabolized
in mitochondria, which stimulates one-carbon metabolism,
to generate NADPH [248]. There are mechanisms in place
to use the mitochondrial matrix space-synthesized NADPH
to prevent product inhibition of enzyme function, the most
important being the fueling of glutathione reductase and
thioredoxin reductase to combat ROS. Alternatively, the
NADPH equivalents can be shuttled to the cytoplasm using
the citrate-pyruvate shuttle. This involves the catabolism of
glutamine and glutamate to alpha-ketoglutarate, which can
lead to IDH2 functioning in the opposite direction of its normal citric acid cycle activity to oxidize NADPH and form isocitrate in the process called reductive carboxylation [249,
250]. Isocitrate can then be further metabolized to citrate.
This citrate, together with other citrate molecules, such as
those derived from R-BHB metabolism, gets shuttled into
the cytoplasm though the mitochondrial citrate carrier protein (CIC) as part of the citrate-pyruvate shuttle (see
Figure 3). In the cytoplasm, the citrate can be converted to
acetyl-CoA and oxaloacetate by ATP-citrate lyase (ACLY).
The acetyl-CoA can function in histone acetylation or fatty
acid synthesis, while the oxaloacetate can be converted to
malate by malate dehydrogenase 1 (MDH1) to restore the
cytoplasmic NAD+/NADH. Malate can then be converted
to pyruvate by NADP+-dependent malic enzyme (ME1),
which concurrently synthesizes NADPH [248]. In the ﬁnal
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step, the pyruvate is shuttled back into the mitochondrial
matrix space, where it is metabolized by pyruvate carboxylase
to form oxaloacetate. The net result is 2ATP + NADH +
NADP+ − >2ADP + NAD+ + NADPH, which contributes to
the restoration of the redox state. The result on the redox
state is very similar to that which occurs due to the NNT
reaction, except the NAD+ and NADPH are formed in the
cytoplasm instead of the mitochondrial matrix. Increased
levels of citrate and acetyl-CoA in the cytoplasm, which
would likely occur as a result of increased shuttle function,
inhibit glycolysis at phosphofructokinase [251] and pyruvate
kinase [252], respectively, which would further aid in the restoration of NAD+/NADH.
In M1-polarized macrophages, citrate-pyruvate shuttle
function can provide NADPH that fuels NADPH oxidasemediated ROS production and contributes to inﬂammation.
These M1 macrophages upregulate the expression of cis-aconitate decarboxylase (IRG1/ACOD1) to convert the citric
acid cycle metabolite cis-aconitate to itaconate, which exerts
anti-inﬂammatory actions to restrain the M1 response, by
inhibiting ETC complex II activity to decrease ROS production and by activating the Nrf2 (NFE2L2) transcriptional regulator. Therefore, inhibitors of CIC and ACLY have been
shown to be anti-inﬂammatory compounds [253], but these
inhibitors may have deleterious eﬀects on the cytoplasmic
and mitochondrial redox states in other cell types. In a
related redox shuttle, the citrate-malate shuttle, the cytoplasmic malate is imported into the mitochondrial matrix and
therefore no cytoplasmic NADPH is synthesized. However,
this shuttle is slightly more energy eﬃcient, using the hydrolysis of only one molecule of ATP. A third shuttle system that
exports citrate from the mitochondrial matrix is the citratealpha-ketoglutarate shuttle. In this shuttle, cytoplasmic citrate
is converted into isocitrate and then further into alphaketoglutarate by cytoplasmic aconitase (ACO1) and isocitrate
dehydrogenase 1 (IDH1), respectively, with the latter reaction
synthesizing NADPH to decrease the cytoplasmic NADP+/NADPH [14]. The alpha-ketoglutarate can then be transported back into the mitochondrial matrix. IDH1 expression
is downregulated in M1-polarized macrophages when measured 24 hours after stimulation with LPS [254] to turn oﬀ
citrate-alpha-ketoglutarate shuttle ﬂux and stimulate citratepyruvate shuttle function. However, two to four hours after
LPS stimulation of macrophages, the alpha-ketoglutaratedependent histone demethylase genes KDM6B [255] and
PHF2 [256] are induced to increase inﬂammation [257].
Therefore, the citrate-alpha-ketoglutarate shuttle proteins
CIC, ACO1, and IDH1 may play a role early in the M1
polarization process to provide nucleocytoplasmic alphaketoglutarate for the function of these histone demethylase
enzymes before the shuttle is turned oﬀ.
8.3.3. Mitochondrial Uncoupling Proteins. Another important mechanism through which a ketogenic diet restores the
mitochondrial NAD+/NADH during mitochondrial ETC
dysfunction is through inducing the expression of mitochondrial uncoupling proteins. The rate of NADH oxidation at
complex I is normally limited by matrix space ADP levels.
The presence of uncoupling proteins removes this limitation
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by allowing protons to ﬂow back into the matrix space to
produce heat. This increases the rate of complex I NADH
oxidation to increase the mitochondrial NAD+/NADH. The
cytoplasmic NAD+/NADH can also be altered by mitochondrial redox changes through malate-aspartate shuttle function. Another beneﬁt of partial mitochondrial uncoupling is
the slight decrease in the mitochondrial membrane potential
that greatly decreases the generation of superoxide at ETC
complexes I and III [258, 259]. One drawback of the
increased expression of uncoupling proteins is the decrease
in ATP generation. The ketogenic diet increases UCP1
expression in brown adipose tissue [240] and UCP2 [95],
UCP4, and UCP5 [260] in the brain. Increases in uncoupling
protein levels have been shown to parallel increases in PGC1α levels. Administration of ketone ester to mice has been
shown to increase the cytoplasmic NAD+/NADH and
decrease the cytoplasmic NADP+/NADPH [16] and likely
utilizes mitochondrial uncoupling and the other mechanisms
listed above to restore redox balance.
8.4. Nrf2 Is Activated by DJ-1 during the Appropriate Redox
Conditions to Restore the Redox State. The mildly elevated
ROS production from R-BHB metabolism from a ketogenic
diet leads to the activation of the Nrf2 transcriptional regulator [261], which stimulates antioxidant response element
(ARE) gene expression. Paraquat, a redox cycling agent,
which greatly increases superoxide production from ETC
complex I, was shown to decrease Nrf2 levels, by a mechanism described in detail below, which was restored by the
administration of R-BHB [262]. Activation of Nrf2 blunts
the cytokine storm through inducing the expression of antioxidant system enzymes including heme oxygenase-1,
SOD2 [263], NADP(H) quinone oxidoreductase (NQO1),
gamma-glutamylcysteine synthetase (GCLC), thioredoxin
(TXN), thioredoxin reductase 1 (TXNRD1) [264], and multiple enzymes for NADPH synthesis including IDH1, malic
enzyme 1 (ME1), and four enzymes of the PPP including
G6PD, 6-phosphogluconate dehydrogenase (PGD), transaldolase, and transketolase [265].
Nrf2 can be activated by hydrogen peroxide when the
ratio of NADP+/NADPH is not too high or too low as shown
in Figure 9(e). For Nrf2 activation to occur, superoxide produced by the ETC in the mitochondrial matrix is converted
into hydrogen peroxide by SOD2. Hydrogen peroxide is then
transported out of the mitochondrial matrix through aquaporins present in the inner mitochondrial membrane. In
the cytoplasm, the redox-sensitive chaperone DJ-1 is activated when cysteine 106 sulfhydryl is oxidized to sulfenic
acid by hydrogen peroxide. This activated form of DJ-1 is
able to release KEAP1 from Nrf2 allowing Nrf2 to enter the
nucleus and induce gene expression. When the NADP+/NADPH is too low, it prevents DJ-1 from being oxidized
and activated. When the NADP+/NADPH is too high, cysteine 106 in DJ-1 becomes overoxidized to sulfonic acid and
DJ-1 is destabilized, ubiquitinated, and degraded by the proteasome, so Nrf2 is not activated [266]. Therefore, R-BHB
metabolism likely preserves the function of Nrf2 by providing the proper NADP+/NADPH ratio, which maintains low
to moderate levels of cytoplasmic hydrogen peroxide.
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8.5. HIF1-α Stabilization by RNS Leads to Proinﬂammatory
Cytokine Production. Hypoxia-inducible factor-1α (HIF-1α)
is the master transcriptional regulator of hypoxic gene
expression. During normoxia, HIF-1α is hydroxylated on
prolines, which stimulates its binding to von Hippel-Lindau
(VHL) protein that targets it for proteasomal degradation.
HIF-1α is also hydroxylated on asparagine residues by FIH1 (factor inhibiting HIF-1-1) to prevent HIF-1α from binding
to its coactivator CBP/p300. During hypoxia, the oxygendependent prolyl and asparaginyl hydroxylases are inactive
stabilizing the transcriptionally active form of HIF-1α. HIF1α can also be activated by ROS or RNS. HIF-1α induces
the expression of glucose transporters, glycolytic enzymes,
and PDK1 to inhibit PDC and shunt glycolysis-derived
carbon ﬂux away from mitochondria when oxidative phosphorylation is compromised. Figure 9(d) shows the Snitrosylation and activation of HIF-1α by peroxynitrite.
S-nitrosylation of HIF-1α prevents the interaction with
VHL for stabilization and inhibits asparagine hydroxylation for activation [267].
HIF-1α can also induce expression of the proinﬂammatory cytokines TNF-α and IL-6 by upregulating NF-κB
[268]. HIF-1α has been shown to be stabilized by increased
pyruvate levels [269], such as those that occur following
PDC inhibition, or by increased succinate levels [270]. The
circadian transcriptional regulator Bmal1, which can be
induced by the hormone melatonin [271], decreases HIF-1α
stability and levels to increase mitochondrial oxidative
metabolism [272]. In lung AECs, stabilization of HIF1-α
was shown to cause ER stress and CHOP-mediated apoptosis
[273]. IAV infection was shown to induce the nuclear translocation of HIF-1α by activating the c-Jun N-terminal kinase
(JNK) signaling pathway to increase proinﬂammatory cytokine expression [274, 275]. However, HIF-1α may also play
a role in suppressing IAV infection as HIF-1α deﬁciency
stimulated IAV replication in AEC II cells by increasing
autophagy [276]. RSV infection was shown to stabilize HIF1α by increasing nitric oxide and peroxynitrite levels [277].
This resulted in increased NF-κB, proinﬂammatory cytokine
levels, and viral replication [278, 279]. Therefore, increasing
levels of R-BHB to decrease RNS levels will likely be able to
decrease the activation of HIF-1α and its downstream
inﬂammatory mediators to mitigate SARS-CoV-2 and other
respiratory viruses.

9. The Effects of R-BHB on Cells of the
Immune System
9.1. Increased NADPH Can Increase or Decrease ROS Levels
Depending upon the Cell Type. NADPH has roles both in
the synthesis of superoxide through its role as a cofactor for
NOX2 and in peroxide detoxiﬁcation through its roles as
cofactors for glutathione reductase and thioredoxin reductase. In most cell types, the lower Km of NADPH for the
reductase antioxidant enzymes allows the antioxidant eﬀect
to predominate [280–282]. However, in some cell types such
as macrophages and neutrophils, the high expression level of
NOX enzymes allows ROS production to predominate. Lung
AECs also have relatively high levels of NOX2, NOX4,
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DUOX1, and DUOX2 [9]. Future studies should address
how altered NADP+/NADPH regulates ROS production in
these cells and if increased ketone body levels increase
NADPH levels in macrophages, neutrophils, and lung epithelial cells to increase NADPH oxidase activity to stimulate
host defenses against pathogens.
In lung epithelial cells, knockdown of G6PD to decrease
NADPH synthesis reduced NOX2 activity to decrease the
antiviral response [283]. In mice, it has been shown that
decreasing NADPH synthesis by inhibiting G6PD and PPP
ﬂux with 6-aminonicotinamide decreased LPS-induced
inﬂammation in a model of acute lung injury [284]. This data
is consistent with the protective eﬀects of the NOX2 inhibitor
for IAV infection [68]. The expression of SOD2 and catalase
is induced by R-BHB-mediated HDAC inhibition [151], so
when R-BHB increases NADPH levels to stimulate NADPH
oxidase activity, it also increases ROS detoxiﬁcation enzymes
to prevent excessive oxidative stress that may lead to a cytokine storm. Increased NADPH levels also have been shown
to stimulate antiviral immunity by decreasing the level of
the NADPH sensor protein HSCARG, which is a negative
regulator of NF-κB transcription. Through this mechanism,
increased NADPH levels were shown to increase expression
of the MX1 and TNF-α genes to decrease human coronavirus
infection [285]. One other potential proinﬂammatory action
of the high NADPH levels from R-BHB metabolism is the
reduction of dihydrobiopterin (BH2) to tetrahydrobiopterin
(BH4). BH4 is an essential cofactor for nitric oxide synthases
and aromatic amino acid hydroxylases [286]. So, increased
NADPH levels may increase nitric oxide synthase activity
leading to RNS production and inﬂammation. However,
when BH4 levels are low, nitric oxide synthases synthesize
superoxide instead of nitric oxide [287]. In this way,
increased NADPH decreases ROS production as it increases
RNS production. This function could potentially decrease
toxic peroxynitrite levels when superoxide is limiting for
its synthesis.
9.2. The Eﬀects of R-BHB and Acetoacetate on Macrophage
Function. Lung-resident macrophage polarization to either
a proinﬂammatory M1 state or an anti-inﬂammatory M2
state is largely controlled by the cytokines secreted by the
other cells present in the environment [288]. R-BHBmediated HDAC inhibition, GPR109A signaling, and inﬂammasome inhibition in these cells likely increase the amounts
of anti-inﬂammatory cytokines, such as IL-10, produced to
stimulate more macrophages to the M2 state. These cytokines also inﬂuence the catabolic pathways that are activated
to fuel cellular energy needs. M1 macrophages have increased
glycolytic activity and lactate production due to the presence
of a dysfunctional citric acid cycle [289]. Increased nitric
oxide levels may inactivate citric acid cycle enzyme aconitase
(ACO2) and the PDC E3 subunit dihydrolipoyl dehydrogenase (DLD). Nitric oxide also may decrease the activities of
ETC complexes I, II, and IV in M1 macrophages [290]. The
dysfunctional citric acid cycle resulted in the accumulation
of citrate that increased fatty acid synthesis [291] and succinate that increased mitochondrial ROS production [270].
This metabolic programming in M1 macrophages likely
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evolved to increase proinﬂammatory cytokine production.
M2 macrophages are programmed to oxidize pyruvate and
fatty acids into acetyl-CoA for normal citric acid cycle function and oxidative phosphorylation [292], which has been
shown to facilitate anti-inﬂammatory IL-10 secretion [293].
Since macrophages lack the enzyme BDH1, they cannot oxidize R-BHB [294], but a ketogenic diet also increases the systemic levels of the ketone body acetoacetate that can be
oxidized by macrophages. The R-BHB/acetoacetate ratio
produced by the liver is proportional to the mitochondrial
NAD+/NADH ratio [295], which is normally around ﬁve
[14], but varies from three to seven. In this regard, acetoacetate but not R-BHB was shown to be metabolized by macrophages to ameliorate liver ﬁbrosis in mice [294]. Neutrophils,
another type of phagocyte contributing to the cytokine
storm, have few mitochondria and very low expression of
ketolytic genes and therefore likely cannot catabolize RBHB or acetoacetate to a signiﬁcant extent.
9.3. A Ketogenic Diet Reduces Lung Inﬂammation by
Reducing Glucose Uptake into ILC2s. A recent study examined the eﬀects of reducing glucose levels, using a ketogenic
diet, on allergen-induced lung inﬂammation in mice. Results
showed that ILC2s in the lungs must increase their uptake of
both fatty acids and glucose from the environment to elicit
allergen-dependent inﬂammation. A ketogenic diet reduced
systemic glucose levels to decrease lung ILC2 glucose uptake
to prevent airway inﬂammation in response to the allergen
[296]. The γδ T cell-ILC2 response activated by the ketogenic
diet in mice [113] was shown to be active in human infants
and children on a normal diet, where it protected them from
inﬂuenza infection [297]. However, this response appears to
be suppressed starting in adolescence and replaced by the
ILC1 system, until it is likely reawakened by the ketogenic
diet. We speculate that the higher activity of the γδ T
cell-ILC2 response in children may be one factor responsible for the less severe symptoms when the SARS-CoV-2
virus infects individuals in this age group. The increased
mortality rate of infected older adults may also be in part
due to the increase in inﬂammation and decline in mitochondrial function and cellular NAD+ and NADPH levels
with aging that decreases metabolic ﬂexibility and the ability to “weather” the cytokine storm.
9.4. HDAC Inhibition and GPR109A Signaling Have AntiInﬂammatory Eﬀects on Dendritic Cells. Dendritic cells play
an important function in presenting antigens to T lymphocytes. Dendritic cells have a high level of oxidative metabolism until they are activated through their TLRs, at which
point they switch to a primarily glycolytic metabolism
[298], which is essential for their activation by providing
cytoplasmic ATP for phospholipid synthesis and signals for
the remodeling and expansion of the secretory system for
its enhanced function in the activated state [299]. The
increased rate of glycolysis in dendritic cells was also required
for their secretion of interferon-α to mitigate IAV infection.
Vaccination against IAV was able to increase glycolytic function in the dendritic cells [300]. Human monocyte-derived
dendritic cells cultured with butyrate showed decreased pro-
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inﬂammatory cytokine and chemokine production [301].
This is likely due to the ability of HDAC inhibition and
GPR109A signaling in dendritic cells to promote Treg cells
[302]. The mechanism may be at least partially metabolic in
nature. Dendritic cells were activated by exposure to LPS in
the presence or absence of butyrate. Butyrate decreased the
oxygen consumption rate and blocked the increase in extracellular acidiﬁcation rate (due to lactate export) used as an
indicator of the glycolytic rate [302]. Butyrate functioning
as an HDAC inhibitor also inhibited the formation of dendritic cells from bone marrow stem cells [303]. Administration of ethyl pyruvate, a cell-permeable pyruvate precursor
with known anti-inﬂammatory properties [304], was shown
to inhibit the activation of dendritic cells by single-strand
RNA that binds to TLR7. Ethyl pyruvate decreased glycolytic
and oxidative metabolism and blocked dendritic cell activation through decreasing ERK and AKT signaling and
decreasing the production of nitric oxide [298]. Therefore,
ethyl pyruvate administration may be a potential therapy to
block the cytokine storm during the later stages of SARSCoV-2 infection.
9.5. Metabolism of R-BHB by B and T Lymphocytes May
Restore Redox and Energy Levels. Increasing R-BHB levels
may also stimulate the immune system by enhancing B or
T lymphocyte function. Recent evidence links the ketogenic
diet in mice with increasing levels of δγ T cells in adipose tissue [114], where the δγ T cells stimulate a thermogenic program [305], in part responsible for the weight loss eﬀects
frequently provided by the ketogenic diet. The ketogenic diet
did not alter the level of ketone body metabolism genes in
lung γδ T cells, but it did upregulate the expression of mitochondrial ETC genes in these cells [113]. Cells of the immune
system express varied amounts of SCOT, used speciﬁcally for
ketolysis, and BDH1, used for both ketogenesis and ketolysis.
B and T lymphocytes possess the greatest amounts of BDH1
and SCOT of the blood cell types [134], so the ketogenic diet
or exogenous ketone treatment may enhance the energy
levels and redox status in these cells more eﬀectively.
9.5.1. A Ketogenic Diet Normalizes the Increased Th17/Treg
Ratio That Occurs due to Disease. There are two important
subtypes of CD4+ T lymphocytes, Th17 and Treg cells. A
ketogenic diet was shown to normalize the proinﬂammatory
Th17/Treg ratio in the blood from epileptic patients [306]. A
high-fat diet may favor the expansion of Treg cells over Th17
cells as Tregs can take up and utilize fatty acids from the environment, while Th17 do not have this ability [307], so Th17
cells must synthesize fatty acids from glucose, which is present at slightly lower levels when consuming the ketogenic
diet [308]. Intermittent fasting that increases R-BHB levels
was also able to restore this ratio in mice with experimental
autoimmune encephalomyelitis (EAE), a model of multiple
sclerosis [309]. HDAC inhibition in naïve T cells leads to
the expression of the FOXP3 transcriptional regulator and
Treg conversion [310]. The longevity-promoting mTOR
inhibitor and antiaging calorie restriction mimetic rapamycin also decreased the Th17/Treg balance. This occurred
through inhibition of glycolysis in Th17 cells and stimulation
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of fatty acid oxidation in Tregs. Fatty acid oxidation was
stimulated by AMP kinase activation [311]. A moderate dose
of butyrate only induced diﬀerentiation of T cells to Treg cells
when administered together with TGF-β1. As TGF-β1 level
is increased by viral infection, this should not pose a problem
for the treatment of SARS-CoV-2 with ketone ester. In addition, HDAC inhibition induces the expression of TGF-β1 in
epithelial cells. However, administering a high dose of butyrate, even when added together with TGF-β1, was ineﬀective
at inducing diﬀerentiation into IL-10-producing Treg cells.
High doses of butyrate resulted in either normal T cells or
IFN-γ-producing Tregs [312]. Therefore, butyrate or RBHB may need to be present in the cell nucleus within a speciﬁc narrow concentration range for the partial inhibition of
HDAC function for the optimal treatment of SARS-CoV-2.
9.5.2. R-BHB Stimulates the Formation of CD8+ Memory T
Cells. CD8+ memory T cells readily oxidize fatty acids and,
like hepatocytes, have the rare ability to simultaneously
express the genes for gluconeogenesis and ketogenesis [313].
The high level of expression of PEPCK1, the rate-limiting step
in gluconeogenesis, resulted in the depletion of cellular oxaloacetate levels. Therefore, the acetyl-CoA formed from fatty
acid beta-oxidation was not able to enter the Krebs cycle and
was therefore used for ketogenesis. The increased R-BHB
levels led to increased beta-hydroxybutyrylation of histone
proteins in the FOXO1 and PGC-1α promoters leading to
increased gene expression. Increased gluconeogenesis led to
increased glucose levels that stimulated the PPP synthesis of
NADPH required for the long-term protection of the CD8+
memory T cells against ROS [314]. Metabolic therapy with
ketone ester should enhance this endogenous epigenetic
program to promote the survival of CD8+ memory T cells to
facilitate immune function when a patient is reexposed to
SARS-CoV-2.

10. Future Perspectives
The data presented here suggest two types of clinical studies
with COVID-19 patients that would provide data on the eﬃcacy of a ketone-based metabolic therapy. These include the
following:
(1) A determination of forced vital capacity by spirometry
of COVID-19 patients consuming ketone ester and a
moderately high-fat diet (forced vital capacity is a
measure of lung function based on taking a full breath
and exhaling as much volume of air as possible)
(2) A randomized trial of COVID-19 patients consuming ketone ester with a moderately high-fat diet with
evaluations of length and severity of infection and
patient mortality
A ketone-based metabolic intervention for COVID-19
patients will likely be initiated at one of the three general
stages of disease progression. During all three stages, the
basic treatment of raising blood ketone levels to 1 to 2 mM
with exogenous ketones, increasing consumption of dietary
fats, and taking enteric-coated sodium bicarbonate to buﬀer
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blood pH will likely be beneﬁcial. The ﬁrst stage is the onset
of disease symptoms. During this stage, a moderate carbohydrate diet will allow normal blood glucose levels to boost
immune cell function. The second stage is when the severity
of symptoms requires hospitalization and/or ventilation. At
this middle stage of infection, a limited carbohydrate diet
would be beneﬁcial to lower glucose metabolism and its associated proinﬂammatory signaling. The third stage is after
ventilator use ceases and diﬃculty in breathing ensues. Once
again, a low-carbohydrate diet at this late stage is hypothesized to facilitate beneﬁcial anti-inﬂammatory processes.
The expected outcomes no matter when treatment is initiated
are a decrease in the incidence of progression to ARDS, protection of organs from oxidative and inﬂammatory damage,
and increased clearance of the virus to shorten the duration
of the infection. Patient data analyzed independently for the
diﬀerent stages of therapy initiation may yield important
insights into the relative time when ketone-based metabolic
intervention is most eﬀective.
The studies suggested above, together with long-term
patient monitoring, may also yield important insights into
the signiﬁcant post-COVID-19 patient complications. There
is evidence from SARS-CoV-1 infections that psychiatric and
chronic fatigue issues continued for four years after infection
[315]. Unfortunately, there are anecdotes from recovered
COVID-19 patients describing similar lingering morbidities.
We further hypothesize that the severity of these morbidities
including chronic fatigue, depression, posttraumatic stress
disorders, panic disorders, and somatoform pain disorders
may be blunted by a ketone-based metabolic therapy due to
the mitigation of cell death and tissue damage.

11. Conclusions
The SARS-CoV-2 virus may become a sustained threat to
global health. This review has described many of the molecular
mechanisms through which an exogenous ketone-based metabolic therapy together with a moderately high-fat diet may
stimulate host cell metabolism and defenses as a possible
treatment to blunt the cytokine storm associated with severe
SARS-CoV-2 infection. A clinical trial testing this therapy on
patients with SARS-CoV-2 is warranted. In addition, further
mouse IAV infection studies will aid in the determination of
permissive dietary conditions under which exogenous ketone
supplementation enhances immune function to facilitate viral
clearance and decrease mortality.
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